Table 2 Quantitative proteomic studies in lung cancer
Biomarker | Types of Sample | Results | Year | Ref. |
|---|---|---|---|---|
ENO1 | Lung cancer tissue | ENO1 was consistently up-regulated in all 14 cases of lung cancer, and suggested that basaloid carcinoma is a unique subtype of NSCLC | 2004 | [75] |
PRDXI, PRDXIII, TXN | Lung cancer tissue | Enhanced lung cancer cell survival and proliferation | 2006 | [76] |
PPIA, TAGLN, TAGLN2 | Lung cancer tissue | Early diagnostic markers for lung cancer | 2009 | [77] |
AGR2, NAPSA | Lung cancer tissue | Stage-related protein candidates for stage IA and IIIA lung adenocarcinoma | 2010 | [43] |
LRG1 | Urinary exosome and lung tissue of NSCLC patient | Non-invasive diagnosis of NSCLC in urine | 2011 | [78] |
AGER, AGR2, AKR1B10, CALCA, CKMTIB, CRABP2, DSG2, FAM3C, PCNA, PTGES3, MCMS, SERPINB5, STRAP | Lung cancer tissue | 84–88% of the protein expression differences of SCC and 44 ADC proteins measured by shotgun analyses of the SCC, ADC and normal pools were confirmed in an independent set of specimens | 2012 | [42] |
Ectopic ATP synthase | Lung tumor xenograft and lung cancer cell | Citreoviridin revealed antitumorigenic effects in lung cancer | 2012 2013 | |
MUC5B | Adenocarcinoma tissue | Aberrant expression of MUC5B was identified in 71% of lung adenocarcinomas in the tumor tissue microarray | 2013 | [79] |
ASNS, CCT chaperonin complex, CHCHD2, GCSH, MARS, MTHFD1, MTHFD1L, MTHFD2, PIP4K2C, PSAT1, SHMT2, TSFM | Lung cancer tissue and xenograft | Integrating the omic data from DNA, RNA, and proteins data sets to reveal new anticancer therapeutic targets for lung cancer | 2014 | [11] |
CEA, CYFRA 21–1, MDK, MMP2, OPN, SCC, TFP1, TIMP1 | Lung cancer tissue, cell-line, and conditioned medium | Biomarker model was developed which accurately distinguished subjects with lung cancer from high risk smokers | 2015 | [8] |
CRP-SAA complex | Serum | Higher expression of CRP-SAA level was associated with severe clinical features of lung cancer | 2015 | [80] |
DPP4, MET, PTPRF | Pleural effusion (PE) | Diagnostic biomarkers of NSCLC from PE proteome | 2015 | [41] |
GLUT1, MCT | Lung cancer cell line | Quantitative proteomics of TMT labeled SCC and ADC suggested that MCT1 and GLUT1 are the promising drug targets or histological markers | 2015 | [48] |
KPNA2 | lung adenocarcinoma cell line | KPNA2-mediated modulation of cell migration in lung cancer | 2015 | [47] |
PDCD4 | NSCLC cell | Longer overall survival of lung cancer patients with PTX treatment (personalized medicine) | 2015 | [46] |
ZYX | Plasma | Early diagnostic marker for NSCLC | 2015 | [44] |
BSG, CEACAM6, ITGB1, LAMP2, SLC3A2 | Lung cancer-derived exosome | NSCLC-related proteins identified from the study of exosomal proteome as promising candidates | 2016 | [40] |
CO4A, GSTP1, HPT | Bronchoalveolar lavage fluid | More sensitive biomarkers were identified by a DIA-based quantitative proteomic approach from bronchoalveolar lavage fluid | 2016 | [45] |
EEF2 | Lung cancer tissue | Clinical tissue studies showed that EF2 protein was significantly overexpressed in LSCC tissues, compared with the adjacent normal lung tissues | 2016 | [81] |
ERO1L, NARS, PABPC4, RCC1, RPS25, TARS | Lung cancer tissue | ERO1L and NARS were positively associated with lymph node metastasis, in which ERO1L overexpression in patient with early stage of adenocarcinoma was associated with poor overall survival | 2016 | [39] |
PON1, SERPINA4 | Serum | Meta-markers might have better specificity and sensitivity than a single biomarker and thus improved the differential diagnosis of lung cancer and lung disease patients | 2016 | [82] |